The data presented in this article are related to the research article entitled "Enhanced Rho-Kinase Activity: Pathophysiological Relevance in Type 2 Diabetes" [1]. Rho-Kinase has attracted a great deal of interest as a novel therapeutic target in cardiovascular diseases. These data describe the observed relationship of Rho-Kinase activity with type 2 diabetic patients. Rho-Kinase activity is determined by immunoblotting of peripheral blood leukocytes with the Phospho-Thr853 in the myosin-binding subunit of myosin light-chain phosphatase. The level of IL-6 is measured using Enzyme-linked immunosorbent assay. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/40).
基金：
National 973 ProgramNational Basic Research Program of China [2012CB518004]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81500292, 81570337]; Hubei Province Natural Science Program [2015CFB455]
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Internal Med, Wuhan, Hubei, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Lei,Tan Lun,Lai Jinsheng,et al.Data for increased Rho kinase activity in type 2 diabetic patients[J].DATA IN BRIEF.2016,9:978-982.doi:10.1016/j.dib.2016.11.032.
APA：
Liu, Lei,Tan, Lun,Lai, Jinsheng,Li, Sheng&Wang, Dao Wen.(2016).Data for increased Rho kinase activity in type 2 diabetic patients.DATA IN BRIEF,9,
MLA：
Liu, Lei,et al."Data for increased Rho kinase activity in type 2 diabetic patients".DATA IN BRIEF 9.(2016):978-982
